Literature DB >> 14597756

The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery.

Shimon Sakaguchi1.   

Abstract

Naturally arising CD4+ regulatory T cells, which engage in the maintenance of immunologic self-tolerance, specifically express FOXP3, which encodes a transcription-repressor protein. Genetic defects in FOXP3 cause IPEX, an X-linked autoimmune/inflammatory syndrome. With FOXP3 as a specific marker for regulatory CD4+ T cells in humans, it is now possible to determine their origin and developmental pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597756      PMCID: PMC228490          DOI: 10.1172/JCI20274

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment.

Authors:  O Annacker; O Burlen-Defranoux; R Pimenta-Araujo; A Cumano; A Bandeira
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

Review 2.  Regulatory T cells: key controllers of immunologic self-tolerance.

Authors:  S Sakaguchi
Journal:  Cell       Date:  2000-05-26       Impact factor: 41.582

3.  Twenty-first century Foxp3.

Authors:  Anne O'Garra; Paulo Vieira
Journal:  Nat Immunol       Date:  2003-04       Impact factor: 25.606

Review 4.  Regulatory T cells in autoimmmunity*.

Authors:  E M Shevach
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

5.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

6.  CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations.

Authors:  L A Stephens; D Mason
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

7.  JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome.

Authors:  T A Chatila; F Blaeser; N Ho; H M Lederman; C Voulgaropoulos; C Helms; A M Bowcock
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 9.  Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis.

Authors:  Eleonora Gambineri; Troy R Torgerson; Hans D Ochs
Journal:  Curr Opin Rheumatol       Date:  2003-07       Impact factor: 5.006

10.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

View more
  63 in total

Review 1.  Tregs and transplantation tolerance.

Authors:  Patrick T Walsh; Devon K Taylor; Laurence A Turka
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  FOXP3 expression and nodal metastasis of breast cancer.

Authors:  Yesim Gökmen-Polar; Mangesh A Thorat; Payal Sojitra; Rashmil Saxena; Sunil Badve
Journal:  Cell Oncol (Dordr)       Date:  2013-08-31       Impact factor: 6.730

Review 3.  Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications.

Authors:  Lequn Li; Vassiliki A Boussiotis
Journal:  J Mol Med (Berl)       Date:  2006-09-14       Impact factor: 4.599

4.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

Authors:  Brygida Bisikirska; John Colgan; Jeremy Luban; Jeffrey A Bluestone; Kevan C Herold
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

5.  Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells.

Authors:  Estelle Bettelli; Maryam Dastrange; Mohamed Oukka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-24       Impact factor: 11.205

Review 6.  Regulatory T cells and type 1 diabetes.

Authors:  Brygida C Bisikirska; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

7.  Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor.

Authors:  Iris Bellinghausen; Bettina König; Ingo Böttcher; Jürgen Knop; Joachim Saloga
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

8.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

9.  CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.

Authors:  Bülent Karagöz; Oğuz Bilgi; Mahmut Gümüs; Alev Akyol Erikçi; Ozkan Sayan; Orhan Türken; Emin Gökhan Kandemir; Ahmet Oztürk; Mustafa Yaylaci
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

Review 10.  Regulatory T Cells for More Targeted Immunosuppressive Therapies.

Authors:  Hazim Allos; Basmah S Al Dulaijan; John Choi; Jamil Azzi
Journal:  Clin Lab Med       Date:  2018-12-20       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.